2022 World Conference on Lung Cancer (ePosters)-EP14.05-019. Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

EP14.05-019. Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021

Back to course

Pdf Summary

This study aimed to analyze the rates of adverse events (AEs) in adults diagnosed with small cell lung cancer (SCLC) in the United States from 2013-2021. The data was obtained from electronic health records (EHR). The study included patients who received first-line (1L) therapy for SCLC. The most common treatment for 1L therapy was platinum-based chemotherapy plus irinotecan/etoposide, but recently four checkpoint inhibitors (CPIs) were approved for SCLC treatment. The researchers conducted a retrospective analysis using data from Flatiron Health's SCLC Enhanced Data Mart.<br /><br />The results showed that out of the 7,528 patients included in the study, 85% initiated 1L treatment. The majority of the patients experienced anemia (91%), neutropenia (55%), and thrombocytopenia (67%). Other common adverse events included elevated liver biochemistry, such as elevated alanine aminotransferase (38%), elevated alkaline phosphatase (54%), and elevated aspartate aminotransferase (43%). Less common adverse events were gastrointestinal symptoms like nausea and diarrhea, experienced by less than 20% of patients.<br /><br />These findings provide valuable information about the real-world safety of SCLC therapies and aid in the development of patient supportive care plans. The study indicates that hematologic adverse events and elevated liver biochemistries are frequent among SCLC patients undergoing systemic treatment. Gastrointestinal symptoms are relatively less common. The study contributes to the overall understanding of the burden of SCLC and can help inform healthcare decision-makers. Acknowledgements were given to the organizations and individuals who contributed to the study.

Asset Subtitle

Robert A Ramirez

Meta Tag

Speaker Robert A Ramirez

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

adverse events

small cell lung cancer

SCLC

electronic health records

platinum-based chemotherapy

checkpoint inhibitors

retrospective analysis

gastrointestinal symptoms

real-world safety

supportive care plans